From the Department of Anesthesiology and Pain Management, MetroHealth Medical Center, Cleveland, Ohio.
Department of Anesthesiology and Pain Medicine, University of Washington, Seattle, Washington.
Anesth Analg. 2020 Oct;131(4):1032-1041. doi: 10.1213/ANE.0000000000005005.
Obstructive sleep apnea (OSA) patients are at increased risk for pulmonary and cardiovascular complications; perioperative mortality risk is unclear. This report analyzes cases submitted to the OSA Death and Near Miss Registry, focusing on factors associated with poor outcomes after an OSA-related event. We hypothesized that more severe outcomes would be associated with OSA severity, less intense monitoring, and higher cumulative opioid doses.
Inclusion criteria were age ≥18 years, OSA diagnosed or suspected, event related to OSA, and event occurrence 1992 or later and <30 days postoperatively. Factors associated with death or brain damage versus other critical events were analyzed by tests of association and odds ratios (OR; 95% confidence intervals [CIs]).
Sixty-six cases met inclusion criteria with known OSA diagnosed in 55 (83%). Patients were middle aged (mean = 53, standard deviation [SD] = 15 years), American Society of Anesthesiologists (ASA) III (59%, n = 38), and obese (mean body mass index [BMI] = 38, SD = 9 kg/m); most had inpatient (80%, n = 51) and elective (90%, n = 56) procedures with general anesthesia (88%, n = 58). Most events occurred on the ward (56%, n = 37), and 14 (21%) occurred at home. Most events (76%, n = 50) occurred within 24 hours of anesthesia end. Ninety-seven percent (n = 64) received opioids within the 24 hours before the event, and two-thirds (41 of 62) also received sedatives. Positive airway pressure devices and/or supplemental oxygen were in use at the time of critical events in 7.5% and 52% of cases, respectively. Sixty-five percent (n = 43) of patients died or had brain damage; 35% (n = 23) experienced other critical events. Continuous central respiratory monitoring was in use for 3 of 43 (7%) of cases where death or brain damage resulted. Death or brain damage was (1) less common when the event was witnessed than unwitnessed (OR = 0.036; 95% CI, 0.007-0.181; P < .001); (2) less common with supplemental oxygen in place (OR = 0.227; 95% CI, 0.070-0.740; P = .011); (3) less common with respiratory monitoring versus no monitoring (OR = 0.109; 95% CI, 0.031-0.384; P < .001); and (4) more common in patients who received both opioids and sedatives than opioids alone (OR = 4.133; 95% CI, 1.348-12.672; P = .011). No evidence for an association was observed between outcomes and OSA severity or cumulative opioid dose.
Death and brain damage were more likely to occur with unwitnessed events, no supplemental oxygen, lack of respiratory monitoring, and coadministration of opioids and sedatives. It is important that efforts be directed at providing more effective monitoring for OSA patients following surgery, and clinicians consider the potentially dangerous effects of opioids and sedatives-especially when combined-when managing OSA patients postoperatively.
阻塞性睡眠呼吸暂停(OSA)患者发生肺部和心血管并发症的风险增加;围手术期死亡率尚不清楚。本报告分析了提交给 OSA 死亡和险兆事件登记处的病例,重点关注与 OSA 相关事件后不良结局相关的因素。我们假设,更严重的结局与 OSA 严重程度、监测强度降低和累积阿片类药物剂量增加有关。
纳入标准为年龄≥18 岁,诊断或疑似 OSA,与 OSA 相关的事件,以及 1992 年或以后和术后 30 天内发生的事件。通过关联检验和比值比(OR;95%置信区间[CI])分析与死亡或脑损伤与其他危急事件相关的因素。
66 例符合纳入标准,已知 OSA 诊断 55 例(83%)。患者年龄中位数为 53 岁(标准差[SD] = 15 岁),美国麻醉医师协会(ASA)分级 III 级(59%,n = 38),肥胖(平均体重指数[BMI] = 38,SD = 9 kg/m);大多数为住院患者(80%,n = 51)和择期手术(90%,n = 56),全身麻醉(88%,n = 58)。大多数事件发生在病房(56%,n = 37),14 例(21%)发生在家中。大多数事件(76%,n = 50)发生在麻醉结束后 24 小时内。97%(n = 64)的患者在事件发生前 24 小时内接受了阿片类药物,三分之二(41 例中的 62 例)也接受了镇静剂。在危急事件发生时,分别有 7.5%和 52%的病例使用了正压通气设备和/或补充氧气。65%(n = 43)的患者死亡或有脑损伤;35%(n = 23)经历了其他危急事件。在导致死亡或脑损伤的 43 例病例中,有 3 例(7%)使用了连续中央呼吸监测。目击的危急事件比无人目击的危急事件更少见(OR = 0.036;95%CI,0.007-0.181;P <.001);(2)有补充氧气时更少见(OR = 0.227;95%CI,0.070-0.740;P =.011);(3)有呼吸监测时比无监测时更少见(OR = 0.109;95%CI,0.031-0.384;P <.001);(4)接受阿片类药物和镇静剂的患者比仅接受阿片类药物的患者更常见(OR = 4.133;95%CI,1.348-12.672;P =.011)。未发现结局与 OSA 严重程度或累积阿片类药物剂量之间存在关联的证据。
无人目击、无补充氧气、无呼吸监测以及同时使用阿片类药物和镇静剂的情况下,更有可能发生死亡和脑损伤。术后为 OSA 患者提供更有效的监测非常重要,当管理 OSA 患者的术后问题时,临床医生应考虑阿片类药物和镇静剂的潜在危险作用,尤其是当两者同时使用时。